Key result
SGLT2 inhibitors linked to ~51% lower AF recurrence after catheter ablation.
Why the study?
SGLT2 inhibitors exhibit potential antiarrhythmic effects, but their influence on atrial fibrillation recurrence after catheter ablation remains unclear.
Does SGLT2i therapy reduce the risk of recurrent atrial fibrillation in patients undergoing catheter ablation?
Meta-Analysis (n=2,165)
Does SGLT2i therapy reduce the risk of recurrent atrial fibrillation in patients undergoing catheter ablation?
Hazard Ratio: 0.49 (95% CI 0.36–0.67)
Absolute Event Rate: 20.8% vs 38%
p-value: p=<0.0001
SGLT2 inhibitor therapy is associated with an approximately 51% lower relative risk of atrial fibrillation recurrence following catheter ablation, a benefit observed independent of diabetic status or ablation modality.
May support adjunctive SGLT2i post-ablation; leaves open causality pending randomized trials.
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) exhibit potential antiarrhythmic effects, but their influence on atrial fibrillation (AF) recurrence after catheter ablation (CA) remains unclear. Objective: This study aimed to assess the association between SGLT2i therapy and the risk of recurrent AF after CA through an updated systematic review and meta-analysis of observational studies. Methods: . The protocol was registered in PROSPERO (CRD42024620765). Results: = .01). Conclusion: SGLT2i therapy is associated with a significantly lower risk of AF recurrence after CA, independent of diabetic status. Further randomized controlled trials are warranted to validate these findings and explore the mechanisms underlying this association.
No takes yet. Share an insight, caveat, or question.
Zuin et al. (2025) conducted a meta-analysis in Atrial fibrillation after catheter ablation (n=2,165). Sodium-glucose cotransporter 2 inhibitors (SGLT2i) vs. No SGLT2i therapy was evaluated on Risk of atrial fibrillation recurrence after catheter ablation (HR 0.49, 95% CI 0.36-0.67, p=<0.0001). Treatment with SGLT2 inhibitors was associated with a 51% relative risk reduction (HR 0.49) of atrial fibrillation recurrence compared to no SGLT2i therapy following catheter ablation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: